此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

TheraSphere日本上市前研究 (INDIGO)

2026年10月19日 更新者:Boston Scientific Corporation

BSJ019T在日本不可切除肝脏恶性肿瘤患者中进行的单臂前瞻性研究(针对标准治疗失败或不适合标准治疗的患者)

To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.

研究概览

地位

招聘中

条件

研究类型

介入性

注册 (估计的)

51

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Hyōgo
      • Nishinomiya、Hyōgo、日本、663-8501
        • 招聘中
        • Hyogo College of Medicine Hospital
        • 接触:
          • Hyogo College of Medicine Hospital Clinical Trial Department
          • 电话号码:+81-798-45-6111
          • 邮箱:chiken02@hyo-med.ac.jp
    • Ishikawa-ken
      • Kanazawa、Ishikawa-ken、日本、920-8641
        • 招聘中
        • Kanazawa University Hospital
        • 接触:
          • Clinical Trial Management Section, Hospital Management Div.
          • 电话号码:+81-76-265-2000
          • 邮箱:irb@adm.kanazawa-u.ac.jp
    • Nara
      • Kashihara、Nara、日本
    • Osaka
      • Sayama、Osaka、日本、589-8511
        • 招聘中
        • Kindai University Hospital
        • 接触:
    • Tokyo
      • Chuo Ku、Tokyo、日本、104-0045
        • 招聘中
        • National Cancer Center Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

[Inclusion criteria based on the clinical evaluation]

  1. Patient aged >18 years at time of consent

  2. Patient is able and willing to participate in the study and has provided written informed consent

  3. Patient who is determined to have failed or not be eligible for standard treatment by the multidisciplinary board

  4. Primary or secondary liver cancer (by histology or imaging)

  5. Measurable disease defined as at least one uni-dimensional measurable liver lesion by CT/MRI (according to RECIST 1.1)

  6. Liver dominant disease (patient prognosis is driven by liver tumor)

  7. Tumor replacement <50% of total liver volume based on visual estimation by the investigator

  8. Expected life expectancy ≥ 3 months or more from the index procedure

  9. ECOG Performance Status score of 0 or 1

  10. Negative pregnancy test in women of child-bearing potential

  11. Adequate contraception for the patient and his/her sexual partner when applicable.

  12. Adequate liver function, as defined by:

    • Child Pugh A or to B7 (HCC)
    • Must have bilirubin ≤ 2 mg/dL
    • ALT and AST must be <5 x ULN
    • Albumin ≥3.0 g/dL
  13. Adequate renal function, as defined by:

    • Serum creatinine must be ≤1.5 x ULN

  14. Adequate hematological function, as defined by:

    • Neutrophil count > 1200 /mm3
    • hemoglobin ≥85 mg/L
    • platelet count >50 x 109/L
    • INR must be <2.0 or >50% prothrombin activity

    [Inclusion Criteria based on the imaging evaluation]

  15. After 99mTc MAA administration, in SPECT/CT imaging, good PVT targeting and uptake of 99mTc MAA, if present

  16. Future liver remnant volume (FLRV) >30% of whole liver volume. FRLV is the volume of liver not planned to be treated with TheraSphere and free of tumor

Exclusion Criteria:

[Exclusion Criteria based on the clinical evaluation]

  1. Vp4 according to the Liver Cancer Study Group of Japan (LCSGJ) portal vein tumor thrombosis classification1

  2. History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically.

  3. Contraindications to angiography and selective visceral catheterization

  4. Received any prior external beam radiation treatment to the liver

  5. Received any prior yttrium-90 microsphere treatment to the liver

  6. Received previous peptide receptor radionuclide therapy (PRRT)

  7. Plan to start systemic anticancer treatment in the next 3 month after the index procedure.

  8. Presence of ongoing adverse event due to prior therapy as judged by the principal investigator or sub-investigator to affect the safety evaluation of the study device.

  9. Evidence of pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease

  10. Undergone any intervention for, or compromise of, the Ampulla of Vater within that last 3 months or patient with biliodigestive anastomosis.

  11. Presence of ascites, clinical or radiological, "trace" of ascites is acceptable.

  12. Presence of Hepatic encephalopathy (Grade ≥2)

  13. Previous liver function decompensation within the last 6 months (ascites, encephalopathy, jaundice)

  14. Patient with infiltrative disease presentation (not suitable for repeated measurement)

  15. Patients who are pregnant or breast-feeding and does not want to stop.

  16. Have any disease or condition that would preclude the safe use of BSJ019T, including concurrent dialysis treatment, or unresolved serious infections

  17. Participating in concurrent clinical studies or interventional clinical studies

  18. Any condition where the Investigator feels the patient would not be able to participate/finish the study

  19. Previous gastrointestinal bleeding related to portal hypertension within the last 3 months (preventive treatment is acceptable)

    [Exclusion Criteria based on the imaging evaluation]

  20. Dose to the lung > 30Gy for a single treatment or cumulative >50 Gy

  21. Evidence of any off-target extrahepatic and liver deposition on 99mTc-MAA that cannot be corrected using angiographic techniques

  22. Cone Beam CT (CBCT) or 99mTc-MAA hepatic arterial perfusion scintigraphy shows poor tumor perfusion and/or poor tumor targeting that would lead to a dose that does not meet the liver dosing criteria as specify in the protocol

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:TheraSphere

TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
使用局部RECIST 1.1标准评估的3个月肝脏疾病控制率(DCR = 完全缓解[CR]、部分缓解[PR]或疾病稳定[SD])。
大体时间:术后3个月
术后3个月

次要结果测量

结果测量
措施说明
大体时间
使用局部RECIST 1.1标准和局部mRECIST标准评估的3个月客观缓解率(ORR = 完全缓解[CR]或部分缓解[PR])
大体时间:术后3个月
术后3个月
使用局部RECIST 1.1标准和局部mRECIST标准评估的6个月时肝脏疾病控制率(DCR)和客观缓解率(ORR)
大体时间:术后6个月
术后6个月
基于本地化的RECIST 1.1标准和本地化mRECIST标准的最佳应答
大体时间:术后6个月内
术后6个月内
接受伴随及BSJ019T治疗后治疗的患者比例,包括后续局部和全身抗肿瘤治疗、手术、介入治疗及最佳支持治疗。
大体时间:索引手术后6个月内
索引手术后6个月内
在固定时间间隔使用EQ-5D问卷评估健康相关生活质量(HRQoL)
大体时间:基线、治疗后1个月、3个月和6个月
基线、治疗后1个月、3个月和6个月
使用FACT-G问卷定期评估与健康相关的生活质量(HRQoL)
大体时间:基线、治疗后1个月、3个月和6个月
基线、治疗后1个月、3个月和6个月
总生存期
大体时间:直至研究完成,平均1年
直至研究完成,平均1年
Safety assessment: rate of treatment emergent adverse events (TEAEs) of any grade, rate of grade 3 or above TEAEs, rate of SAEs of any causality and rate of SAEs related to treatment with TheraSphere.
大体时间:Through 6-months post index procedure

All AEs will be evaluated using the standardized grading criteria (National Cancer Institute- Common Terminology Criteria for Adverse Events- Version 5.0 (NCI-CTCAE v 5.0))

Through 6-months post index procedure
Technical success in delivering the Y-90 microspheres
大体时间:During the index procedure

Technical success is determined successful if residual waste is ≦2% with optimal tumor targeting and extrahepatic deposition is not seen on post treatment imaging, and the success rate of entire of the subjects will be summarized.

During the index procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Koichiro Yamakado, MD, PhD、Hyogo Medical University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月22日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2025年9月24日

首先提交符合 QC 标准的

2026年1月26日

首次发布 (实际的)

2026年1月30日

研究记录更新

最后更新发布 (实际的)

2026年10月21日

上次提交的符合 QC 标准的更新

2026年10月19日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅